Vinay Prasad, M.D., is out again as the chief medical and scientific officer for the U.S. Food and Drug Administration (FDA). Last July, Prasad tendered his resignation in the wake of a fiery attack ...

Welcome to another installment of This Week at FDA, your weekly source for updates—big and small—on FDA, drug, and medical device regulation and what we’re reading from around the web. This week, FDA ...

Add Yahoo as a preferred source to see more of our stories on Google. This marks Prasad's second departure from the FDA as CBER head. Photo by Marvin Joseph/The Washington Post via Getty Images. Vinay ...

WHITE OAK, Md. — The controversial head of the Food and Drug Administration's vaccines and biologics unit, Dr. Vinay Prasad, will leave the agency at the end of April. FDA Commissioner Dr. Marty ...

The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial decisions ...

WASHINGTON — The Food and Drug Administration's embattled vaccine chief, Dr. Vinay Prasad, is once again leaving the agency — the second time in less than a year that he's departed after controversial ...

Homeland Security Secretary Kristi Noem is out, as Donald Trump names Markwayne Mullin to replace her. Will the DHS personnel change also affect ICE policy? Plus, does the U.S. have enough air-defense ...

Add Yahoo as a preferred source to see more of our stories on Google. The FDA's vaccine chief is set to leave the agency by the end of April, a spokesperson with the Department of Health and Human ...

Successor to be named before Prasad's departure Prasad had received criticism for his division's handling of rare disease treatments Prasad to return to UCSF March 6 (Reuters) - The controversial head ...

Vinay Prasad is leaving his post as director of the Center for Biologics Evaluation and Research. The top vaccine and biologics drug official in the U.S. Food and Drug Administration will step down in ...

Editor's Note: This is a developing story. Please check back for updates. After a tumultuous tenure marked by recent clashes with the biopharma industry, Vinay Prasad, M.D., will be departing his post ...